Vertex Pharmaceuticals Inc (NASDAQ: VRTX) has reported E.P.S. of $3.55 for its fourth fiscal quarter (ending December 31) versus $3.76 for the same period a year ago — a decline of -6%. Relative to the consensus estimate of $4.02, this was a shortfall of $-0.47. For the latest four quarters through December 31, E.P.S. were $-2.08 compared to $14.05 a year ago — a decline of -115%.
Recent Price Action
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) stock closed at $469.97 on 2/10/25 after a slight gain of 0.1%. This advance was accompanied by normal trading volume. The stock has risen 1.8% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Vertex Pharmaceuticals has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Vertex Pharmaceuticals has a neutral Appreciation Score of 55 and a slightly negative Power Rating of 34, and the Negative Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment